Lol plex, none taken. The more conversation we have about all business associated with anavex the better as it helps everyone have a better understanding of our investment in this company
The article rather clearly lays out what is (rather authoritatively) known about the importance of sleep — it causes neurons to dissemble excess new synapses where memories are stored. Too many of these new synapses overwhelm normal cognition and memory.
All of this supports the homeostasis-restoring outcomes of Anavex 2-73. In normal brain cells, a night’s sleep allows the enzymes of the neuron to mobilize and transport the excess wastes and extraneous new synapses to the exterior, never allowing them to accumulate. But, because the rough endoplasmic reticula become separated from their associated mitochondria in the Alzheimer’s disease state, the rough ER can’t make or properly fold normal waste-clearing proteins (specific enzymes). Normal cell clean-up is fatally disrupted.
Alzheimer’s patients can sleep for extensive periods, with no cognition improvements. If the health-giving protein (enzymes) are not made, amyloid and tau proteins will accumulate, disrupting normal neuron functions.
Let me add this.
All of this is abundantly clear to all parties involved in any potential Anavex collaboration. This may be deep cellular chemistry (inscrutable “brain chemistry”) to both retail AVXL investors and stock consultants.
But the principals involved in any potential collaboration know full well the profound efficacies and CNS disease applications for Anavex 2-73. They have or are brain biochemists. They’ve scrutinized the many application reports in murines (rats and mice), and know how those can be accurately interpreted to apply to Homo sapiens.